Table 2.

Summary of adverse events of the MAD study considered probably or possibly related to study treatment

	PRI‐002
	Cohort 1 (160 mg)	Cohort 2 (320 mg)	Placebo	Total
System organ class, preferred term, n (%)	n = 8	n = 7	n = 8	n = 23
Nervous system disorders
Disoriented three times	1	0	0	1
	(12.5%)			(4.3%)
Headache (grade 2)	0	0	1	1
			(12.5%)	(4.3%)
Total number of events	1	0	1	2
	(12.5%)		(12.5%)	(8.7%)